Literature DB >> 12466370

Growth hormone blunts protein oxidation and promotes protein turnover to a similar extent in abdominally obese and normal-weight women.

Madelon M Buijs1, Johannes A Romijn, Jacobus Burggraaf, Marieke L De Kam, Adam F Cohen, Marijke Frölich, Frans Stellaard, A Edo Meinders, Hanno Pijl.   

Abstract

Abdominally obese individuals have reduced 24-h plasma GH concentrations. Their normal plasma IGF-I levels may reflect GH hypersensitivity. Alternatively, obesity-associated hyposomatotropism may cause less biological effect in target tissues. We therefore determined whole-body responsiveness to the anabolic effects of GH in abdominally obese (OB) and normal weight (NW) premenopausal women. A 1-h iv infusion of GH or placebo was randomly administered to six NW (body mass index, 21.1 +/- 1.9 kg/m(2)) and six OB (body mass index, 35.5 +/- 1.5 kg/m(2)) women in a cross-over design. Endogenous insulin, glucagon and GH secretion was suppressed by infusion of somatostatin. Whole-body protein turnover was measured using a 10-h infusion of [(13)C]-leucine. GH administration induced a similar plasma GH peak in NW and OB women (49.8 +/- 10.4 vs. 45.1 +/- 5.6 mU/liter). GH, compared with placebo infusion, increased nonoxidative leucine disposal, P < 0.0001) and endogenous leucine appearance (R(a), P = 0.0004) but decreased leucine oxidation (P = 0.0051). All changes were similar in both groups. Accordingly, whole-body GH responsiveness, defined as the maximum response of nonoxidative leucine disposal, leucine R(a), and oxidation per unit of GH, was not different in OB and NW women (0.25 +/- 0.18 vs. 0.19 +/- 0.17 micro mol/kg.h, 0.21 +/- 0.23 vs. 0.13 +/- 0.17 micro mol/kg.h, and -0.10 +/- 0.08 vs. -0.08 +/- 0.05 micro mol/kg.h, respectively). These results indicated that whole-body tissue responsiveness to the net anabolic effect of GH is similar in OB and NW women. Hence, we inferred that hyposomatotropism may promote amino acid oxidation and blunt protein turnover in abdominal obesity. However, hyposomatotropism cannot account for all anomalous features of protein metabolism in abdominally obese humans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466370     DOI: 10.1210/jc.2002-020927

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

2.  Enhancement of muscle mitochondrial function by growth hormone.

Authors:  Kevin R Short; Niels Moller; Maureen L Bigelow; Jill Coenen-Schimke; K Sreekumaran Nair
Journal:  J Clin Endocrinol Metab       Date:  2007-11-13       Impact factor: 5.958

Review 3.  Metabolic and Endocrine Consequences of Bariatric Surgery.

Authors:  Isabel Cornejo-Pareja; Mercedes Clemente-Postigo; Francisco J Tinahones
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-19       Impact factor: 5.555

Review 4.  GH/IGF-1 Abnormalities and Muscle Impairment: From Basic Research to Clinical Practice.

Authors:  Betina Biagetti; Rafael Simó
Journal:  Int J Mol Sci       Date:  2021-01-02       Impact factor: 5.923

5.  Coupling Complete Blood Count and Steroidomics to Track Low Doses Administration of Recombinant Growth Hormone: An Anti-Doping Perspective.

Authors:  Luca Narduzzi; Corinne Buisson; Marie-Line Morvan; Alexandre Marchand; Michel Audran; Yves Le Bouc; Emmanuelle Varlet-Marie; Magnus Ericsson; Bruno Le Bizec; Gaud Dervilly
Journal:  Front Mol Biosci       Date:  2021-06-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.